Badger-founded Constantiam Biosciences secures $2M from the NIH
Constantiam Biosciences is a biotechnology start-up company founded by three Wisconsin grads — Nicholas Schafer ’08, Daniel Goldman ’07, and Norman Ong ’07 — focused on interpreting the vast diversity of human genetic variation to improve outcomes for patients afflicted by cancer, neurodegeneration, and cardiovascular disease. The company has been awarded a $2M Small Business Innovation Research (SBIR) grant from the National Human Genome Research Institute (NHGRI) to develop technologies aimed at addressing medically inactionable variants of uncertain significance (VUS) uncovered in clinical genetic tests. Constantiam’s technologies enable classification of VUS to improve patient outcomes across a wide variety of medical conditions, unlocking the power of precision medicine.
More Alumni Notes
Cassie Schwartz, a 2003 graduate, recently completed and successfully defended her doctoral dissertation, titled “Narratives of Jewish Americ...